Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of bendamustine
hydrochloride, mitoxantrone, and rituximab can help to control follicular lymphoma.
The safety of this drug combination will also be studied.